Pivotal data are due soon with the Claudin18.2-targeting ADC sonesitatug vedotin.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
The group is aiming for accelerated approval with the upcoming Alpacca trial.
Sunmo succeeds in a setting very similar to Starglo's.
Zanzalintinib prevails in all comers, but full data will show if the win was driven by a subgroup.
The registrational part 2 of bezuclastinib's Summit trial reads out in July.
When your investment case breaks down, why not just do the decent thing?
